What was studied?
A randomized phase 3 trial compared mazdutide with a specified dulaglutide regimen in adults receiving background oral diabetes medicines.
What did the researchers report?
Mazdutide met the trial's non-inferiority and superiority criteria for glycated-hemoglobin change, with greater weight reductions. Gastrointestinal events were more common.
What are the limits?
The comparison is against the particular comparator regimen tested. It cannot rank every available treatment or establish equivalence between the trial product and supplier materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.